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OBJECTIVE—To determine whether the phosphoinositide 3-kinase
(PI3K) catalytic subunits p110-a and p110-b play a role in liver
steatosis induced by a high-fat diet (HFD).
RESEARCH DESIGN AND METHODS—Liver-speciﬁc p110-a
and p110-b knockout mice and control animals for each group
were fed an HFD or normal chow for 8 weeks. Biochemical assays
and quantitative real-time PCR were used to measure triglyceride,
expression of lipogenic and gluconeogenic genes, and activity of
protein kinases downstream of PI3K in liver lysates. Fatty acid
uptake and incorporation into triglycerides were assessed in iso-
lated hepatocytes.
RESULTS—Hepatic triglyceride levels in HFD-fed p110-a
2/2
mice were 84 6 3% lower than in p110-a
+/+ mice, whereas the
loss of p110-b did not signiﬁcantly alter liver lipid accumulation.
p110-a
2/2 livers also showed a reduction in atypical protein ki-
nase C activity and decreased mRNA and protein expression of
several lipogenic genes. Hepatocytes isolated from p110-a
2/2
mice exhibited decreased palmitate uptake and reduced fatty
acid incorporation into triglycerides as compared with p110-
a
+/+ cells, and hepatic expression of liver fatty acid binding pro-
tein was lower in p110-a
2/2 mice fed the HFD as compared with
controls. Ablation of neither p110-a nor p110-b ameliorated glu-
cose intolerance induced by the HFD, and genes involved in
gluconeogenesis were upregulated in the liver of both knockout
animals.
CONCLUSIONS—PI3K p110-a, and not p110-b, promotes liver
steatosis in mice fed an HFD. p110-a might exert this effect in part
through activation of atypical protein kinase C, upregulation of
lipogenesis, and increased uptake of fatty acids. Diabetes 60:
1483–1492, 2011
N
onalcoholic fatty liver disease (NAFLD) is one
of the most common liver disorders worldwide
and may affect up to one-third of adults in the
U.S. (1,2). NAFLD is especially prevalent in
people with type 2 diabetes, obesity, and/or hyperlipid-
emia. Simple steatosis in NAFLD may progress to steato-
hepatitis, advanced ﬁbrosis, cirrhosis, and liver failure.
Liver steatosis is characterized by the accumulation of
excess triglycerides resulting from an imbalance between
synthesis, uptake, secretion, and oxidation of fatty acids. It
is well established that a high-fat diet (HFD) can induce
hepatic steatosis in humans and rodents. HFDs can cause
an increase in expression of the transcription factors sterol
regulatory element binding protein 1c (SREBP-1c; a major
activator of lipogenic genes) and peroxisome proliferator-
activated receptor g (PPAR-g), and lipogenic genes such
as fatty acid synthase (FAS) and acetyl-CoA carboxylase
(ACC) in mouse liver (3,4). It would seem paradoxical to
have increased lipogenesis in the face of excess dietary
fats, and some studies have questioned whether HFD-
induced liver steatosis is mainly a result of de novo
lipogenesis (5). Another possible mechanism for high
triglyceride accumulation in the liver could be increased
uptake of dietary fatty acids from the blood. Fatty acid
uptake in the liver is thought to be mediated by several
transport proteins, including members of the fatty acid
transport protein family and the highly expressed liver
fatty acid binding protein (L-FABP). Deletion of these
genes decreases fatty acid uptake in hepatocytes and
partially protects mice from HFD-induced liver steatosis
(6–9).
Class IA phosphoinositide 3-kinases (PI3Ks) are heter-
odimers consisting of a catalytic subunit (p110-a, p110-b,
or p110-d) bound to one of several regulatory subunits
(collectively called p85). Analysis of the function of cata-
lytic (p110-a and p110-b) and regulatory (p85-a and p85-b)
subunits using knockout mice has shown that these
enzymes regulate lipid and glucose metabolism in the liver
under normal feeding conditions (10–12). Production of
the second messenger phosphatidylinositol 3,4,5-tris-
phosphate by PI3Ks leads to activation of Akt and atypi-
cal protein kinase C (aPKC)-l and -z (13–15). It has been
proposed that Akt controls hepatic glucose metabolism
downstream of PI3K in part by inhibiting expression of the
major gluconeogenic genes phosphoenolpyruvate carbox-
ykinase (PEPCK) and glucose 6-phosphatase (G6PC),
whereas aPKC regulates lipid metabolism by upregulating
the expression of SREBP-1c (12,16–18). However, two
recent reports showed that liver steatosis in mice fed
an HFD was improved in the absence of hepatic Akt2 (19)
or upon inhibition of aPKC using adenoviral delivery of
a kinase-dead enzyme (20), suggesting that both of these
kinases can promote hepatic lipid accumulation under
conditions of high dietary fat.
These results also suggest that PI3Ks are involved in
HFD-induced liver steatosis. To test this hypothesis, we
derived liver-speciﬁc p110-a– and p110-b–null animals
from conditional PI3K knockout mouse strains previously
generated by us (21). Using these animals, we show that
ablation of p110-a, but not p110-b, attenuates liver steatosis
induced by an HFD.
RESEARCH DESIGN AND METHODS
Materials. Antibodies were purchased from the following sources: for p110-a
from BD Biosciences; for p110-b, p110-d, Akt, aPKC (recognizes PKC-z and -l),
insulin receptor substrate-1 (IRS-1), IRS-2, Foxo1, SREBP-1, and S6 from
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ORIGINAL ARTICLESanta Cruz Biotechnology; for pan-p85 and glycogen synthase kinase 3b
(GSK3b) from Millipore; for phospho-Akt, phospho-GSK3b (Ser 9), phospho-S6
(Ser 240/244), ACC (recognizes ACC1 and ACC2), phospho-Foxo1, and FAS
from Cell Signaling; for L-FABP from Abcam; and for actin and glyceraldehyde
3-phosphate dehydrogenase (GAPDH) from Sigma-Aldrich.
Animals. p110-a
Flox/Flox and p110-b
Flox/Flox mice in a mixed 129 and C57BL/6 J
genetic background (21) were bred to albumin-Cre (Alb-Cre) transgenic mice
(Jackson Laboratory) to produce liver-speciﬁc p110-a and p110-b knockout
mice. The one copy of Alb-Cre in both lines was detected by primers that span
part of the Cre sequence. Only male mice were used in this study. p110-a
Flox/Flox;
Alb-Cre
+ mice (referred to as p110-a
2/2) were compared with p110-a
Flox/Flox
( r e f e r r e dt oa sp 1 1 0 - a
+/+) littermates and p110-b
Flox/Flox;Alb-Cre
+ mice (referred
to as p110-b
2/2) were compared with p110-b
Flox/Flox (referred to as p110-b
+/+)
littermates. Mice were analyzed between 8 and 16 weeks of age and were housed
on a 12-h light/12-h dark cycle. For HFD experiments, 8-week-old mice were
singly housed and fed either an HFD containing 45 kcal% fat (rodent diet D12451;
Research Diets) or standard rodent chow for 8 weeks. Body weight and food
intake were monitored weekly. Before the start and at the end of the study, mice
were weighed and anesthetized and dual energy X-ray absorptiometry (DEXA)
scanning was performed using the PIXImus2 DEXA scanner (Faxitron X-ray
Corporation, Wheeling, IL) to determine body fat content. All animal-related ex-
perimental protocols were approved by the Stony Brook University Institutional
Animal Care and Use Committee.
Western blotting. To determine tissue levels of PI3K, equal amounts of
lysate protein were incubated for 2 h at 4°C with a phosphotyrosine peptide
(CDMSKDESVDYpVPMLDMK) coupled to agarose (21). After four washes,
the beads were boiled in SDS sample buffer and the proteins were sub-
jected to Western blotting. For in vivo insulin signaling, mice were fasted
overnight and then injected intraperitoneally with 2 units/kg body wt of
human insulin (Novolin; Novo Nordisk) or an equal volume of saline. At
different times after injection, mice were killed and livers were removed
and frozen in liquid nitrogen. Liver extracts were subjected to SDS-PAGE and
immunoblotting as previously described (22). Signals were visualized using
horseradish peroxidase-linked secondary antibodies and chemiluminescence
reagents.
Kinaseassays.For PI3K assays, micewere fasted overnight, then anesthetized
andinjectedthroughtheinferiorvenacavawithinsulin(2units/kg).Liverswere
removed 5 min later and frozen in liquid nitrogen. Extracts were incubated
overnight at 4°C with anti-IRS-1 or anti-IRS-2 antibody. Immunocomplexes
were pulled down with protein A agarose and PI3K was assayed as previously
described (22). For Akt and aPKC, mice on normal chow were fasted over-
night and then injected intraperitoneally with insulin (2 units/kg) or an equal
volume of saline. Livers were removed 15 min later and frozen in liquid ni-
trogen. For mice on the HFD, livers were removed from mice fasted for 6 h
without any injections. Extracts were incubated overnight at 4°C with anti-
bodies to Akt or aPKC. The immunoprecipitates were assayed as previously
described (23).
Liver triglyceride content. Mice fasted for 6 h were killed, and tissues were
frozen in liquid nitrogen. Frozen tissues (20–100 mg) were homogenized in PBS
and extracted with chloroform and methanol (3:1). The extracts were dried
overnight and resuspended in isopropanol. An appropriate volume of the sus-
pension was assayed using a triglyceride assay kit (Sigma-Aldrich).
Hepatocyte isolation. Primary hepatocytes from mice fed normal chow were
isolated by collagenase perfusion (24). Mice were anesthetized with ketamine/
xylazine, and the liver was perfused ﬁrst with Krebs Ringer buffer (122 mmol/L
NaCl, 5.6 mmol/L KCl, 5.5 mmol/L D-glucose, 2.5 mmol/L NaHCO3, and 20
mmol/L HEPES [pH 7.4]) with 0.1 mmol/L EGTA, followed by perfusion with
Krebs Ringer buffer with 1.37 mmol/L CaCl2 and 28 mg/50 mL collagenase
(Worthington, type I). Both buffers were run at 5 mL/min for 10 min. Hepato-
cytes were harvested, and viability was examined by trypan blue exclusion.
Hepatocytes were plated on collagen-coated plates in Dulbecco’s modiﬁed
Eagle’sm e d i u m / F 1 2 - H a m ’s medium supplemented with 10% FBS, 1% antibiotic/
antimycotic reagent (Sigma-Aldrich), 1 g/L fatty acid-free BSA, and 13 insulin-
selenium-transferrin (Gibco). Cells were allowed to recover overnight before
using them for experiments.
Long chain fatty acid uptake and incorporation into triglycerides. For
fatty acid uptake, hepatocytes in PBS were incubated at 37°C for 30 min with
or without 100 nmol/L insulin and then increasing concentrations of [
3H]
palmitate bound to defatted BSA in a 3:1 molar ratio were added. After 1 min,
uptake was stopped by adding 200 mmol/L phloretin/0.1% BSA at 4°C. The cells
were washed three times with ice-cold PBS, lysed in 0.1 mol/L NaOH, 0.03%
SDS, and protein content was measured (BCA assay; Thermo Scientiﬁc).
Cellular uptake of [
3H]palmitate was determined by scintillation counting and
normalized to total protein. [
3H]palmitate incorporation into triglycerides was
performed as described previously with slight modiﬁcations (25). Hepatocytes
were incubated for 2 h with or without 100 nmol/L insulin and with 0.04 mmol/L
[
3H]palmitate bound to defatted BSA in a molar ratio of 3:1. Following
treatment, cells were scraped off the plate in PBS and pelleted at 800 g at 4°C.
The cells were extracted with 1 mL 2-propanol:heptane (4:1) for 1 h at room
temperature with intermittent vortexing. After addition of 2 mL water and 2 mL
heptane, the upper heptane phase containing triglyceride was collected and
washed with ethanolic NaOH (ethanol:0.1 mol/L NaOH, 1:1). Triplicate samples
of the washed heptane phase were dried in scintillation vials overnight. [
3H]
palmitate incorporated into triglyceride was determined by scintillation counting
and normalized to the number of cells plated.
Glucose tolerance test and blood chemistry. For glucose tolerance tests,
mice fasted overnight were injected intraperitoneally with 2 g/kg dextrose and
tail blood glucose was measured at various times using a One Touch Ultra Mini
glucose monitor (Life Span, Milpitas, CA). Serum insulin levels were measured
by ELISA (Crystal Chem, Chicago, IL). Serum levels of liver enzymes, bilirubin,
cholesterol, triglyceride, albumin, and total protein were measured by Anilytics
(Gaithersburg, MD).
Analysis of liver glycogen. Mice fasted for 6 h were killed, and livers were
frozen in liquid nitrogen. Frozen livers (20–100 mg) were digested in 30% KOH
for 20 min at 100°C. Macromolecules were precipitated by the addition of
two volumes of ethanol followed by overnight incubation at 220°C. The next
day the samples were centrifuged at 3,000 rpm for 15 min at 4°C and the
supernatant was removed. Macromolecules were resuspended in water and
precipitated again by addition of two volumes of ethanol and incubation
overnight at 220°C. Macromolecules were washed in 70% ethanol, and gly-
cogen was hydrolyzed by digestion in 84% H2SO4. Glucose in the samples was
determined colorimetrically as compared with glucose standards after ad-
dition of anthrone.
Histology. Tissues were formalin ﬁxed and embedded in parafﬁn using
standard procedures. Sections (5 mm) were cut and stained with hematoxylin
and eosin (H-E) or trichrome for standard microscopy. Frozen liver sections
(8 mm) were stained with Oil Red O (Sigma-Aldrich) and counterstained with
hematoxylin to visualize lipids.
Quantitative real-time (RT)-PCR. Quantitative RT-PCR was performed as
described previously (26). Total RNA was extracted from livers using Tri
Reagent (Sigma-Aldrich), and cDNA was generated using the iScript cDNA
Synthesis kit (Bio-Rad). TaqMan Universal PCR Master Mix and TaqMan gene
expression assays for Fasn (Mm00662312_g1), Srebf1 (Mm00550338_m1),
Pparg (Mm01184323_m1), Fabp1 (Mm00444340_m1), Pck1 (Mm01247057_g1),
G6pc (Mm00839363_m1), Acaca (Mm01304285_m1), and 18S RNA
(HS99999901_s1) were purchased from Applied Biosystems. RT-PCR was
performed on duplicate samples using a DNA Engine Opticon 2 System (MJ
Research). The abundance of mRNA of the gene of interest relative to 18S
RNA was determined using the equation r =2
(C
T18S RNA 2
C
Tgene of interest
),
where CT is the number of cycles needed to achieve a preset threshold value
of ﬂuorescence. The results are expressed as fold change in r as compared
with control samples.
Statistical analysis. Student t test was used for comparisons between groups
using Excel Analysis Tool (Microsoft). Data are presented as mean 6 SEM or
% of control. P , 0.05 was considered to be signiﬁcant.
RESULTS
Phenotypes of liver-speciﬁc p110-a and p110-b
knockout mice. Hepatocyte-speciﬁcp 1 1 0 - a– and p110-b–
deﬁcient mice were generated as described in RESEARCH
DESIGN AND METHODS. Western blotting conﬁrmed that p110-a
or p110-b was appropriately ablated (Fig. 1A) and that the
gene deletion was speciﬁcally targeted to the liver (Fig.
1B). Both knockout mouse strains appeared normal and
were fertile. At 9 weeks of age, there were no signiﬁcant
differences between control and knockout animals in body
weight, liver protein content, or serum biochemical pa-
rameters that assess liver function (Table 1). However, the
liver weight as a percentage of body weight and the liver
triglyceride content of p110-a
2/2 mice were both signiﬁ-
cantly decreased as compared with p110-a
+/+ mice (Table 1).
These values were not signiﬁcantly different between
p110-b
+/+ and p110-b
2/2 mice (Table 1). The liver gly-
cogen content was reduced in both groups of knockout
mice, and serum glucose and insulin were elevated in
the p110-b
2/2 mice as compared with controls (Table
1). Gross examination of livers from 9-week-old mice
revealed that the general lobular architecture of the
organ was preserved in both knockout mouse strains.
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vious abnormalities such as necrosis or ﬁbrosis
(Supplementary Fig. 1).
Effect of PI3K ablation on hepatic insulin signaling.
To investigate the effect of PI3K ablation on insulin sig-
naling in the liver, mice were injected with insulin and
Western blotting was used to assess the time course of Akt
phosphorylation. Insulin-induced Akt phosphorylation at
Ser473 was decreased in the p110-a
2/2 and p110-b
2/2
livers, but phosphorylation at Thr308 was less affected
(Fig. 2A). Insulin-stimulated phosphorylation of GSK3b
and S6 was also rather indifferent to the loss of p110-a
2/2
or p110-b
2/2 (Fig. 2A). We next assayed kinase activities
in liver lysates of mice treated for 15 min with saline or
hormone. Insulin activation of Akt was reduced by 49 6 4%
in the p110-a
2/2 livers as compared with p110-a
+/+ controls,
whereas the activation of Akt was similar in the p110-b
2/2
and control livers (Fig. 2B). Because the residual Akt acti-
vation in p110-a
2/2 liver appeared to be sufﬁcient to in-
crease the phosphorylation of GSK3b and S6 in response to
insulin (Fig. 2A), we also examined Akt phosphorylation
sites in the transcription factor Foxo1, which controls
PEPCK expression (27). Insulin induction of Thr24 phos-
phorylation still occurred in p110-a
2/2 liver, but the response
at Ser319 was lost (Supplementary Fig. 2). Insulin-induced
phosphorylation of Foxo1 at Ser256 was not observed in the
liver of control or p110-a
2/2 mice, although it was readily
detected in HepG2 cells (data not shown). Activation of
aPKC was completely blocked in the p110-a
2/2 liver but
unaffected in the p110-b
2/2 tissue (Fig. 2C).
Finally, PI3K activity in IRS-1 and IRS-2 immunopreci-
pitates of liver lysates prepared from insulin-injected mice
was measured. There was a 52 6 6% reduction in IRS-1–
associated PI3K activity (Fig. 2D) and an 87 6 10% re-
duction in IRS-2–associated PI3K activity (Supplementary
Fig. 3) in the p110-a
2/2 samples as compared with con-
trols. IRS-1– and IRS-2–associated PI3K activity was not
reduced in the p110-b
2/2 liver lysates as compared with
p110-b
+/+ samples (Fig. 2D and Supplementary Fig. 3). To
determine which PI3K isoform might be contributing to the
residual PI3K activity in the p110-a
2/2 liver, IRS-1 immu-
noprecipitates were assayed in the presence of PI3K
inhibitors IC87114 (p110-d selective), TGX-221 (p110-b
selective), or PI-103 (broad spectrum). IC87114 caused
a7 76 3% inhibition of PI3K activity in the p110-a
2/2 im-
munoprecipitate and a 51 6 3% decrease in the p110-a
+/+
immunoprecipitate (Fig. 2D). Treatment with TGX-221 did
not inhibit the PI3K activity in p110-a
2/2 samples, whereas
PI-103 inhibited the activity by 84 6 3% (Fig. 2D). Western
blot analysis of liver extracts detected p110-d in the livers
of all four strains of mice (Fig. 1A). These data show that
insulin signaling through IRS-1 and IRS-2 to activate Akt
and aPKC is mediated by p110-a but not p110-b. The
FIG. 1. Ablation of p110-a2 and p110-b2PI3K in the liver. A: Class IA
PI3Ks in liver lysates from mice of the indicated genotypes were pulled
down with a phosphotyrosine peptide and the bound proteins were
examined on Western blots probed with the indicated antibodies.
Recombinant PI3K-a (p110-a/p85-a), PI3K-b (p110-b/p85-a), and PI3K-d
(p110-d/p85-a)w e r el o a d e da sc o n t r o l s .B: Class IA PI3Ks in lysates from
hearts, white adipose tissue (WAT), skeletal muscle, and livers of p110-
a
2/2 and p110-b
2/2 mice were pulled down with a phosphotyrosine pep-
tide, and the bound proteins were examined on Western blots probed
with the indicated antibodies. Recombinant PI3K-a and PI3K-b were
loaded as controls.
TABLE 1
Phenotypic comparison of p110 control and knockout mice on normal chow
p110-a
+/+ p110-a
2/2 p110-b
+/+ p110-b
2/2
Body weight (g) 22 6 22 2 6 1.6 22 6 0.8 22 6 1.3
%Body fat 18.3 6 0.2 18.6 6 0.5 17.2 6 0.2 16.9 6 0.2
Liver as % of body weight 4.00 6 0.01 3.00 6 0.02* 4.00 6 0.02 4.00 6 0.03
Liver triglyceride (mg/g)† 5.7 6 0.9 4.1 6 0.2* 5.1 6 0.7 5.0 6 0.2
Liver protein (mg/g) 346 6 53 288 6 20 326 6 23 312 6 52
Liver glycogen (mg/g)† 14.2 6 0.3 5.8 6 0.1* 13 6 0.3 1.3 6 0.3*
Blood chemistry†
ALT (units/L) 65 6 19 44 6 2 232 6 21 156 6 33
AST (units/L) 180 6 44 215 6 40 264 6 67 271 6 92
ALP (units/L) 85 6 15 89 6 10 85 6 14 88 6 2
Total bilirubin (mg/dL) 0.1 6 0.02 0.3 6 0.01 0.2 6 0.01 0.2 6 0.1
Cholesterol (mg/dL) 50 6 93 9 6 27 4 6 10 64 6 5
Triglyceride (mg/dL) 50 6 44 1 6 46 3 6 12 59 6 7
Albumin (g/dL) 2.3 6 0.1 2.1 6 0.2 2.7 6 0.2 2.3 6 0.3
Total protein (g/dL) 3.6 6 0.3 3.3 6 0.4 4.4 6 0.4 3.9 6 0.1
Glucose (mg/dL) 119 6 2 118 6 1 109 6 4 150 6 4*
Insulin (ng/mL) 1.96 6 0.32 1.82 6 0.21 0.75 6 0.11 3.46 6 0.53*
Data are means 6 SE; N = 6 per group. ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase. *P , 0.05.
†Animals were fasted for 6 h.
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FIG. 2. Insulin signaling in p110-null livers. A: Liver lysates from fasted mice treated intraperitoneally without or with insulin (2 units/kg body wt)
for the indicated times were analyzed by Western blotting. B and C: Fasted mice were injected intraperitoneally with saline or insulin (2 units/kg
body wt). Livers were collected 15 min later, and lysates were prepared and assayed for Akt (B) or aPKC (C) kinase activity. *P < 0.05 by t test
(N = 3 for all groups). D: Mice were fasted overnight and then injected through the inferior vena cava with insulin (2 units/kg body wt). Livers were
collected 5 min later, and lysates were subjected to immunoprecipitation with IRS-1 antibody. The immunoprecipitates for p110-a
+/+ and p110-a
2/2
(left panel) were assayed for PI3K activity in the presence of vehicle, 500 nmol/L PI-103 (PI), 50 nmol/L TGX-221 (TGX), or 5 mmol/L IC87114
(IC). Values are normalized to the average PI3K activity in p110-a
+/+ samples assayed in the absence of inhibitors. The immunoprecipitates for
p110-b
+/+ and p110-b
2/2 (right panel) were assayed without any additions (N = 3 for all groups). Values shown are mean 6 SEM.
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activated PI3K activity in the liver is contributed by
p110-d.
Effect of PI3K ablation on HFD-induced liver
steatosis. To investigate the role of PI3K isoforms in
the development of HFD-induced liver steatosis, these
four mouse strains were fed an HFD for 8 weeks. All four
groups of mice gained weight (9.8 6 0.2 g) and body fat
(average increase of 42 6 0.4% by DEXA scan). There
were no signiﬁcant differences in these parameters be-
tween p110-deﬁcient animals and their p110
+/+ controls.
All four strains of mice were hyperinsulinemic and hy-
perglycemic under HFD conditions (Table 2). There were
no signiﬁcant differences in serum triglyceride levels be-
tween the knockout and control animals on the HFD
(Table 2). However, ablation of p110-a markedly reduced
liver lipid accumulation as compared with controls as
assessed by Oil Red O staining of liver sections (Fig. 3A).
Hepatic triglyceride levels in HFD-fed p110-a
2/2 mice
were 84 6 3% lower than in p110-a
+/+ mice (Fig. 3B). In
contrast, loss of p110-b did not signiﬁcantly affect liver
lipid accumulation in mice fed the HFD (Fig. 3A and B).
aPKC and Akt activities were assayed in liver extracts of
HFD-fed mice that were fasted for 6 h. aPKC activity was
signiﬁcantly decreased in the p110-a
2/2 livers as com-
p a r e dw i t hp 1 1 0 - a
+/+ controls (Fig. 3C), but there was no
signiﬁcant difference in Akt activity between these two
groups (Fig. 3D). In contrast, neither aPKC nor Akt was
affected by ablation of p110-b (Fig. 3C and D). Thus re-
duced aPKC activity in p110-a
2/2 livers correlates with
their resistance to HFD-induced steatosis.
Ablation of p110-a decreases lipogenic gene expression.
HFDs can upregulate the expression of lipogenic genes in
livers of mice (3,4). Using quantitative RT-PCR, we found
that under fed conditions the expression of FAS, PPAR-g,
SREBP-1, and ACC1 was upregulated in both p110-a
+/+ and
p110-a
2/2 mice fed the HFD as compared with normal chow
(Fig. 4A). However, with both diets the FAS, PPAR-g,a n d
SREBP-1 mRNA levels were signiﬁcantly lower in p110-a
2/2
livers than in p110-a
+/+ livers (Fig. 4A). Western blotting
showed that in mice fed normal chow, the SREBP-1 protein
level was lower in p110-a
2/2 livers than in p110-a
+/+ livers
(Fig. 4B). In mice fed the HFD, the hepatic FAS, ACC, and
SREBP-1 protein levels were signiﬁcantly reduced in
p110-a
2/2 ascomparedwithp110-a
+/+ mice(Fig. 4B).A sim-
ilar analysis of livers from mice fasted for 6 h also showed
increases in FAS, PPAR-g, and SREBP-1 mRNAs in p110-a
2/2
and p110-a
+/+ mice fed the HFD as compared with normal
chow (Fig. 4C). With both diets the FAS and PPAR-g mRNA
levels were signiﬁcantly lower in p110-a
2/2 livers than in
control livers (Fig. 4C). Western blotting showed that in
fasted mice on normal chow, the FAS protein level was
lower in p110-a
2/2 livers than in p110-a
+/+ livers (Fig. 4D).
By contrast, hepatic FAS protein levels after a 6-h fast were
similar in HFD-fed p110-a
2/2 and p110-a
+/+ mice (Fig. 4D).
Ablation of p110-b did not affect the expression of these genes
in the livers of fasted mice on either diet (Supplementary
Fig. 4). These results suggest that decreased lipogenesis
contributes to the lower hepatic triglyceride content in p110-
a
2/2 mice fed normal chow (Table 1) and may be a major
reason why liver triglyceride accumulation is attenuated in
p110-a
2/2 mice fed an HFD.
Ablation of p110-a reduces hepatic fatty acid uptake.
Mice with defective hepatic uptake of long chain fatty
acids are partially protected from liver steatosis when fed
an HFD (6,8,9). To determine whether long chain fatty acid
uptake is affected by loss of p110-a,[
3H]palmitate uptake
was assayed in hepatocytes isolated from p110-a
+/+ and
p110-a
2/2 mice. p110-a–null hepatocytes exhibited de-
creased [
3H]palmitate uptake as compared with p110-a
+/+
cells at most of the fatty acid concentrations tested (Fig. 5A).
In agreement with previously published data (28), insulin
had little or no stimulatory effect on fatty acid uptake in
hepatocytes of either genotype (Supplementary Fig. 5A).
To determine whether lower fatty acid uptake could con-
tribute to decreased steatosis in the p110-a
2/2 mice, we
measured [
3H]palmitate incorporation into triglycerides
and found that this process was markedly reduced in p110-
a
2/2 hepatocytes as compared with control cells in the
absence (Fig. 5B) or presence (Supplementary Fig. 5B)o f
insulin. We next examined the expression of L-FABP,
which regulates fatty acid uptake, intracellular transport,
and metabolism in the liver and promotes the development
of liver steatosis in response to an HFD (9). Although L-
FABP mRNA levels were higher in both p110-a
+/+ and
p110-a
2/2 mice fed the HFD as compared with normal
chow, the knockout livers showed lower expression than
controls under both conditions (Fig. 5C). Livers from p110-
a
2/2 mice also contained decreased amounts of L-FABP
protein as compared with controls, especially in HFD-fed
mice (Fig. 5D). These results suggest that p110-a
2/2 mice
are protected from HFD-induced liver steatosis at least in
part because of downregulation of L-FABP and reduced
fatty acid uptake and incorporation into triglycerides.
Effect of PI3K ablation on HFD-induced glucose
intolerance. In addition to hepatic steatosis, an HFD in-
duces glucose intolerance in mice. Indeed, glucose tolerance
tests showed that both p110-a
+/+ and p110-b
+/+ mice deve-
loped this phenotype after 8w e e k so nt h eH F D( F i g .6 A and
B). Ablation of neither p110-a nor p110-b ameliorated HFD-
induced glucose intolerance. In fact, p110-a
2/2 mice exhibi-
ted more severe glucose intolerance than p110-a
+/+ animals
on the HFD (Fig. 6A). Similarly, HFD-induced increases
in PEPCK gene expression were not inhibited by abla-
tion of p110-a or p110-b (Supplementary Fig. 6). Inter-
estingly, expression of G6PC was elevated in p110-a
2/2 and
TABLE 2
Blood chemistry comparison of p110 control and knockout mice
on HFD
p110-a
+/+ p110-a
2/2 p110-b
+/+ p110-b
2/2
ALT (units/L) 42 6 53 9 6 95 1 6 16 48 6 8
AST (units/L) 360 6 58 245 6 67* 406 6 131 366 6 115
ALP (units/L) 62 6 18 43 6 88 6 6 20 36 6 5
Total bilirubin
(mg/dL) 0.3 6 0.15 0.2 6 0.04 0.1 6 0.04 0.1 6 0.04
Cholesterol
(mg/dL) 126 6 19 83 6 24 105 6 14 134 6 21
Triglyceride
(mg/dL) 48 6 11 41 6 74 7 6 16 46 6 7
Albumin (g/dL) 2.3 6 0.2 1.9 6 0.2 2.6 6 0.2 2.4 6 0.2
Total protein
(g/dL) 4.3 6 0.3 3.3 6 0.4 4.5 6 0.4 4.3 6 0.3
Glucose
(mg/dL) 179 6 31 208 6 35 195 6 14 186 6 13
Insulin
(ng/mL) 4.94 6 0.92 5.42 6 0.42 4.21 6 2.50 5.46 6 1.72
Data are means 6 SE; N = 3 per group. ALT, alanine aminotransfer-
ase; AST, aspartate aminotransferase; ALP, alkaline phosphatase.
*P , 0.05. Animals were fasted for 6 h.
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2/2 animals fed normal chow as compared with their
controls, but no further increase in G6PC mRNA was seen in
the knockout livers of mice fed the HFD (Supplementary
Fig. 6).
DISCUSSION
In this study, we found that HFD-induced hepatic steatosis
was virtually eliminated in liver-speciﬁc p110-a
2/2 mice,
whereas ablation of p110-b had no effect on liver tri-
glyceride accumulation. Recent studies have shown that
inhibition of hepatic aPKC or Akt2 in mice ameliorates
liver steatosis caused by an HFD (19,20). Indeed, the HFD-
fed p110-a
2/2 mice herein exhibited lower aPKC activity
than the controls. A decrease in aPKC activity is thought to
improve steatosis by reducing the expression of SREBP-1c
and its lipogenic gene targets (20). Our ﬁnding that mRNA
and/or protein levels of SREBP-1, FAS, PPAR-g, and ACC
were reduced in ab libitum–fed p110-a
2/2 mice on the
HFD is consistent with the idea that lipogenesis is reduced
in the liver of these animals. Expression of some lipogenic
genes was also suppressed in the liver of p110-a
2/2 mice
fed normal chow, as was the hepatic triglyceride content.
These results suggest that p110-a ablation also inhibits
lipid synthesis in the liver under normal dietary conditions.
Another source of triglycerides in the liver is uptake of
fatty acids from the blood. It was estimated that about 74%
of the triglyceride fatty acids in the liver of patients with
NAFLD comes from serum nonesteriﬁed fatty acids plus
dietary fatty acids (29). Several proteins have been identi-
ﬁed that mediate fatty acid uptake into the liver, including
L-FABP (30). In vitro studies demonstrated increased fatty
acid uptake in cells with upregulated expression of L-FABP
(31,32), and L-FABP knockout mice showed reduced fatty
acid uptake in hepatocytes and decreased hepatic tri-
glyceride when fed an HFD (8,9). We found that fatty acid
uptake and incorporation into triglycerides were signiﬁ-
cantly decreased in p110-a
2/2 hepatocytes. HFD caused an
increase in L-FABP protein in control mice, but this in-
crease was strongly inhibited in p110-a
2/2 mice. Our results
suggest that reduced fatty acid uptake as a consequence of
decreased L-FABP expression is an important mechanism that
protects p110-a
2/2 mice from HFD-induced liver steatosis.
Additional studies are needed to identify the mechanisms
by which p110-a regulates L-FABP expression.
The hepatic insulin signaling pathways that suppress
gluconeogenesis and activate lipogenesis have been pro-
posed to bifurcate after Akt, with activation of mTORC1
(the rapamycin-sensitive complex of mammalian target of
rapamycin) being required for insulin-stimulated induction
of SREBP-1c but not for suppression of PEPCK (33). We
found that expression of SREBP-1 was suppressed in the
liver of p110-a
2/2 mice on normal chow, but insulin acti-
vation of mTORC1 (as assessed by S6 phosphorylation)
was intact. The apparent discrepancy in mTORC1 signal-
ing and SREBP-1 expression between our work and that of
Li et al. (33) could be because of differences between the
two experimental systems, e.g., use of isolated rat hep-
atocytes treated with insulin for 6 h (33) versus mice
injected with insulin for shorter times (this work). Another
possibility is that the reduction in lipogenenic gene ex-
pression in the p110-a
2/2 liver occurs independently of
insulin signaling. Elucidation of a possible role of p110-a in
selective hepatic insulin signaling requires further study.
Previous studies using liver-speciﬁc p110-a– or p110-b–
deﬁcient mice examined the role of these PI3Ks in regu-
lating glucose and lipid homeostasis under normal dietary
conditions (10,11). Sopasakis et al. (11) examined chronic
FIG. 3. Loss of p110-a blocks hepatic steatosis induced by an HFD. Mice were fed a 45 kcal% fat diet for 8 weeks. A: Frozen liver sections (8 µm)
were stained with Oil Red O to visualize neutral lipids and counterstained with hematoxylin. Scale bars = 200 µm. B: Liver triglyceride (TG)
content. *P < 0.005 by t test (N =6 ) .C: aPKC kinase activity assayed in liver lysates from mice fasted for 6 h. *P < 0.01 by t test (N =3 ) .D: Akt
kinase activity assayed in liver lysates from mice fasted for 6 h (N = 3). Values are mean 6 SEM. (A high-quality digital representation of this ﬁgure
is available in the online issue.)
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Flox/Flox line to Alb-Cre mice)
and acute (created by injecting adult p110-a
Flox/Flox mice
with adenovirus expressing Cre) p110-a knockout mouse
models. Both types of p110-a knockout mice exhibited
reduced insulin sensitivity, impaired glucose tolerance,
increased gluconeogenesis, hyperleptinemia, and hyper-
insulinemia. There was almost a complete loss of insulin-
induced IRS-1–associated PI3K activity and marked reduction
in insulin activation of Akt and aPKC in the liver of chronic
p110-a knockout mice (11). The acute p110-a knockout
FIG. 4. Loss of p110-a affects the expression of genes and proteins regulating lipid metabolism. A: Quantitative RT-PCR analysis of mRNA levels in
livers of mice fed ad libitum an HFD or normal chow (NC). *P < 0.05 by t test (N =6 ) .B: Liver lysates from ad libitum-fed mice were analyzed by
Western blotting with the indicated antibodies. Bands were quantiﬁed using densitometry. *P < 0.01 by t test. C: Quantitative RT-PCR analysis of
mRNA levels in livers of mice fasted for 6 h. *P < 0.05 by t test (N =6 ) .D: Liver lysates from mice fasted for 6 h were analyzed on Western blots,
and the bands were quantiﬁed by densitometry. *P < 0.01 by t test. Values are means 6 SEM.
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and expression of lipogenic genes, similar to our p110-a
2/2
animals fed normal chow. The acute liver-speciﬁc p110-b
knockout mice examined by Jia et al. (10) showed intact
insulin activation of Akt in the liver, increased gluconeo-
genesis and hepatic PEPCK mRNA levels, hyperinsulinemia,
hyperleptinemia, glucose intolerance, and reduced insulin
sensitivity. Several of these phenotypes were also observed
in our p110-b
2/2 mice on normal chow.
Activation of PI3K signaling controls many aspects of
the insulin-mediated regulation of glucose metabolism.
Insulin suppression of gluconeogenic genes is thought to
be mediated by Akt-dependent phosphorylation and in-
hibition of Foxo1 (27). It was surprising that p110-b
2/2
mice on normal chow were hyperglycemic with increased
expression of hepatic PEPCK and G6PC, since insulin ac-
tivation of Akt appeared normal in these animals. This
result suggests that an Akt-independent mechanism con-
trols PEPCK expression in the p110-b
2/2 liver. Although
insulin activation of PI3K and Akt were both attenuated in
the liver of our p110-a
2/2 mice fed normal chow, these
effects did not lead to hyperglycemia. We suspect that the
normal glucose levels in our p110-a
2/2 mice fed normal
chow are because of residual Akt activation in the liver,
which is adequate to signal downstream. Indeed, insulin-
stimulated phosphorylation of GSK3b, S6, and Thr24 in
Foxo1 was unaffected in the p110-a
2/2 liver, although phos-
phorylation of Ser319 in Foxo1 was suppressed. The re-
sidual Akt activation might be a result of recruitment of
p110-d into the IRS-1 complex following insulin stimula-
tion. The p110-a
2/2 mice used here may have a compen-
satory upregulation of p110-d. However, we found that
about 50% of the insulin-induced IRS-1–associated PI3K
activity from control p110-a
+/+ livers is contributed by
p110-d, based on its sensitivity to IC87114. It is possible
that variable amounts of p110-d in insulin-responsive tis-
sues in different strains of mice could affect insulin action
and the phenotypes of p110-a knockout animals. The
FIG. 5. Loss of p110-a attenuates fatty acid uptake in hepatocytes. Hepatocytes were isolated from p110-a
+/+ and p110-a
2/2 mice fed normal chow
as described in RESEARCH DESIGN AND METHODS. A: Cells were incubated with increasing amounts of [
3H]palmitate/BSA at a 3:1 molar ratio for 1 min.
[
3H]palmitate uptake into the cell was then measured. *P < 0.001 by t test. B: Hepatocytes were incubated with [
3H]palmitate/BSA for 2 h, and
[
3H]palmitate incorporated into cellular triglycerides was then measured. *P < 0.001 by t test. C: Quantitative RT-PCR analysis of mRNA levels in
livers of p110-a
+/+ and p110-a
2/2 mice fed an HFD or normal chow (NC). *P < 0.05 by t test (N =6 ) .D: Liver lysates were analyzed by Western
blotting with the indicated antibodies. Bands were quantiﬁed using densitometry. *P < 0.005 by t test. Values are means 6 SEM of three in-
dependent experiments done in triplicate.
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Ref. 11 was not reported. Future studies using p110-d
knockout mice will help clarify the role of this PI3K iso-
form in regulating hepatic metabolic processes.
The degree of glucose intolerance was more severe in
our p110-a
2/2 mice as compared with controls when they
were fed the HFD. Lipotoxicity caused by fatty acid me-
tabolites such as diacylglycerol or ceramide is thought to
be central to the pathogenesis of hepatic insulin resistance
(34). Hepatic steatosis is generally accompanied by fasting
hyperglycemia and glucose intolerance, but a disconnect
between liver steatosis and hepatic insulin resistance has
been observed in some mouse models. For example, mice
overexpressing acyl-CoA:diacylglycerol acyltransferase 1
or 2 in the liver developed hepatic steatosis with increased
amounts of putative lipotoxic intermediates, but they did
not develop hepatic insulin resistance or hyperglycemia
(35). Similar to our p110-a
2/2 mice on the HFD, ablation of
hepatic Akt2 in the ob/ob background reduced liver stea-
tosis but did not improve hyperglycemia (19). One expla-
nation for our result is that a lipotoxic metabolite that
causes hepatic insulin resistance is still produced in the liv-
ers of p110-a
2/2 mice on the HFD, despite the overall re-
duction in hepatic lipid. Alternatively, reduced insulin
signaling through p110-a might be part of the mechanism
that leads to the HFD-induced increase in hepatic glucose
production, so genetic ablation of this enzyme would
worsen this condition. Altered lipid metabolism in the liver
might also promote hormonal and metabolic changes in
extrahepatic tissues that contribute to HFD-induced hy-
perglycemia and glucose intolerance in p110-a
2/2 animals.
Even though glucose intolerance was not improved in
p110-a
2/2 mice, reversing steatosis might be beneﬁcial
because it would block the progression to more serious
liver disease.
In conclusion, our data indicate that p110-a but not p110-
b plays a pivotal role in the development of liver steatosis
induced by HFD feeding. The mechanism of reduced lipid
accumulation in the p110-a
2/2 liver is likely the result of
decreased lipogenesis because of suppression of lipogenic
genes and lower fatty acid uptake resulting from decreased
expression of L-FABP. Because NAFLD is becoming a
public health problem of epidemic proportions, a better
understanding of the pathways that regulate lipid accumu-
lation in the liver is crucial for developing effective thera-
pies for this important medical condition.
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